Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Vedere Bio II
Headquarters: Cambridge, MA, United States of America
Website: N/A
Year Founded: 2020
Status: Out of Business
BioCentury | Jul 26, 2023
Management Tracks
New CEOs for Catalyst, FibroGen, Pheon and Tae
Plus: Nicole Sweeny named chief commercial officer of KalVista
BioCentury | Apr 4, 2023
Regulation
April 3 Quick Takes: Padcev label expanded to first-line urothelial cancer
Plus: Ascendis’ market cap melts as thyroid program hits FDA snag and updates from Apellis, Vedere and Vertex-CRISPR
BioCentury | May 20, 2022
Discovery & Translation
Optimizing CNS tropism for AAVs at ASGCT
Directed evolution, genetic library screening and peptide modifications were the most common strategies presented
BioCentury | Apr 26, 2022
Management Tracks
Stoffels becomes Galapagos board chairman
Plus Vedere Bio II and management moves at Jnana, Flare, DeepCure and more
BioCentury | Apr 12, 2022
Management Tracks
Consylman now at Vedere Bio II
Plus Neuron23 hires Jackson and updates from Sitryx, Illumina, Alto and more
BioCentury | Jun 22, 2021
Management Tracks
Wigerinck to leave Galapagos; plus Kymera, Alladapt, Nurix, Alchemab, Novome and more
Piet Wigerinck will step down this year after serving as CSO for nine years at Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), overseeing the Belgian biotech’s programs from the discovery of
BioCentury | May 18, 2021
Finance
May 18 Quick Takes: Temasek backs Wilson, Yamada to form G2 Bio; plus PathAI, Interius, Vedere II and more
Singapore-based Temasek will supply $200 million to G2 Management Co. Inc. to foster the development of therapies from the University of Pennsylvania's Gene Therapy Program, led by James Wilson.
BioCentury | Oct 30, 2020
Deals
Via takeout of Atlas-grown optogenetic play for $150M up front, Novartis adds to gene therapy arsenal
Vedere Bio II spins out with vision restoration and preservation programs
Items per page:
1 - 8 of 8